Skip to content

Ottobock's Stock Market Debut Scheduled for 2025 – Revealing Fresh Information

Ottobock intends to conduct an Initial Public Offering (IPO) by the end of 2025, with a goal of raising €100 million in capital.

Ottobock's Anticipated Stock Market Debut in 2025 - Revealed Additional Information
Ottobock's Anticipated Stock Market Debut in 2025 - Revealed Additional Information

Ottobock's Stock Market Debut Scheduled for 2025 – Revealing Fresh Information

Ottobock Announces Planned IPO and New Phase of Growth

German MedTech company Ottobock is set to embark on a new phase of growth with the announcement of an upcoming Initial Public Offering (IPO), scheduled between late September and mid-October 2025. The IPO, which will be managed by a consortium including BNP Paribas, Deutsche Bank, and Goldman Sachs, aims to provide the company with increased financial flexibility and enable it to invest more strongly in new technologies.

Ottobock, a global champion in the field of Human Bionics, has transformed its technology platform, innovation pipeline, and patient access over the years. The company's mission remains unchanged: to empower people to maintain or regain their mobility.

The planned IPO comes at a time when Ottobock has consistently demonstrated impressive growth. In the past few years, the company has achieved double-digit organic revenue growth in its core business and continuously increased margins. This financial success has positioned Ottobock as a key player in the German stock market landscape, enriching it with another exciting company in the coming weeks.

Oliver Jakobi, CEO of Ottobock, has announced that the proceeds from the IPO will be used to reduce debt, make acquisitions, invest in technologies, and expand the company's international presence. The goal is to further cement Ottobock's position as a global leader in the field of Human Bionics and continue setting new standards in the industry.

As Ottobock prepares for this new phase, it remains committed to its mission of empowering people. The company aims to expand its global presence and continue to provide innovative solutions that enable people to live active, independent lives.

In the coming weeks, investors and stakeholders will be closely watching Ottobock's IPO, eager to see how this MedTech champion will continue to shape the future of Human Bionics.

Read also:

Latest